Debbie has 17 years of global drug development and commercialization experience at small and large biotech/pharmaceutical companies, managing global cross-functional planning across hematology/oncology, immuno-oncology, and oncology therapeutic areas.
Since 2017, Debbie has served as the Executive/Senior Director of Program & Alliance Management at Maverick Therapeutics (acquired by Takeda). She led the global cross-functional planning and alliance management for the Conditionally Active Bispecific T cell engagers (COBRA™) in solid tumors programs. While at Coherus Biosciences, Inc and Jazz Pharmaceutical, she led cross-functional planning for the U.S. approval and launch of UDENYCA® (pegfilgrastim-cbqv) and for the US launch of Defitelio® (defibrotide sodium).
Earlier in her career, Debbie served in project management roles culminating to Director, Global Program Management – Strategic Operations and Commercialization at Amgen. She led clinical planning of several oncology programs contributing to global approvals of Nplate® (romiplostim) and Vectibix® (panitumumab), the implementation of product strategies for marketed product Nplate®, and the alliance oversight for Nplate® and several early development programs. She started her industry career at Takeda Pharmaceutical as an Associate Project Management consultant.
Debbie received her B.S. in Biology from the University of Illinois at Chicago and her MBA and Master of Project Management from the Keller Graduate School of Management of DeVry University.